Drawing for ORAMAB

USPTO serial 79216395

ORAMAB

Reviewed by CopyMark Law Group

Reg. 5472201Status 709
Filing date
Status date
Registration date
May 22, 2018
Examiner
TORRES, ELIANA
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ORAMAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Monte L. Falcoff/Jessica S. Sachs

Monte L. Falcoff/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.5445 Corporate DriveSuite 200Troy, MI 48098

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for treating inflammatory diseases of the digestive tractSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 3, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 12, 2026INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Jan 29, 2026XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jan 29, 2026XXCRGENERIC MADRID TRANSACTION CREATED—
Aug 6, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 6, 2024C71TCANCELLED SECTION 71—
Apr 15, 2021CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Apr 9, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 3, 2021CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Mar 5, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 29, 2018FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 6, 2018XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Sep 6, 2018XXCRGENERIC MADRID TRANSACTION CREATED—
Aug 22, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 22, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 6, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 6, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 14, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 24, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 5, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 5, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 5, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 14, 2017RFNTREFUSAL PROCESSED BY IB—
Sep 26, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 26, 2017RFRRREFUSAL PROCESSED BY MPU—
Sep 21, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 20, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 19, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 18, 2017DOCKASSIGNED TO EXAMINER—
Sep 15, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 14, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance